Skip to content

Skip to secondary menu

Jehovah’s Witnesses



Uterotonic Agents

Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, non-inferiority trial.

Blum J, Winikoff B, Raghavan S, Dabash R, Ramadan MC, Dilbaz B, Dao B, Durocher J, Yalvac S, Diop A, Dzuba IG, Ngoc NT.

Source‎: Lancet 2010;375(9710):217-23.

Indexed‎: PubMed 20060162

DOI‎: 10.1016/S0140-6736(09)61923-1

Rectally administered misoprostol versus intravenous oxytocin infusion during cesarean delivery to reduce intraoperative and postoperative blood loss.

Chaudhuri P, Banerjee GB, Mandal A.

Source‎: Int J Gynaecol Obstet 2010;109(1):25-9.

Indexed‎: PubMed 20070961

DOI‎: 10.1016/j.ijgo.2009.11.009

Comparison of two oxytocin regimens to prevent uterine atony at cesarean delivery: a randomized controlled trial.

Munn MB, Owen J, Vincent R, Wakefield M, Chestnut DH, Hauth JC.

Source‎: Obstet Gynecol 2001;98(3):386-90.

Indexed‎: PubMed 11530117

A randomized clinical trial of preoperative versus postoperative misoprostol in elective cesarean delivery.

Ragab A, Barakat R, Alsammani MA.

Source‎: Int J Gynaecol Obstet 2016;132(1):82-4.

Indexed‎: PubMed 26522140

DOI‎: 10.1016/j.ijgo.2015.06.057

Intravenous sulprostone infusion in the treatment of retained placenta.

Stefanovic V, Paavonen J, Loukovaara M, Halmesmäki E, Ahonen J, Tikkanen M.

Source‎: Acta Obstet Gynecol Scand 2013;92(4):426-32.

Indexed‎: PubMed 22862433

DOI‎: 10.1111/j.1600-0412.2012.01506.x

Prostaglandins for preventing postpartum haemorrhage.

Tunçalp Ö, Hofmeyr GJ, Gülmezoglu AM.

Source‎: Cochrane Database Syst Rev 2012;(8):CD000494.

Indexed‎: PubMed 22895917

DOI‎: 10.1002/14651858.CD000494.pub4

Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage.

Westhoff G, Cotter AM, Tolosa JE.

Source‎: Cochrane Database Syst Rev 2013;10:CD001808.

Indexed‎: PubMed 24173606

DOI‎: 10.1002/14651858.CD001808.pub2

The medical section of is designed as an informational resource primarily for use by clinicians and other health-care professionals. It provides neither medical advice nor treatment recommendations and does not substitute for an appropriately qualified health-care provider. The clinical literature cited is not published by Jehovah’s Witnesses, but it outlines transfusion-alternative strategies that might be considered. It is the responsibility of each qualified health-care provider to maintain awareness of new information, discuss options for care, and assist patients in making choices in accord with their medical condition, wishes, values, and beliefs. Not all listed strategies are appropriate or acceptable to all patients.

Patients: Always seek the advice of your doctor or other qualified health-care provider regarding medical conditions or treatments. Check with a doctor if you suspect you are ill.

The use of this website is governed by its terms of use.